Why the study?
Does finerenone slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease?
Population
People with non-diabetic chronic kidney disease, including those with glomerular disease
Design
Editorial
Authors
Loading...
Finerenone may have a broader role in nephrology practice by slowing kidney disease progression and reducing cardiovascular risk in non-diabetic CKD.
Does finerenone slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease?
Finerenone may have a broader role in nephrology practice by slowing kidney disease progression and reducing cardiovascular risk in non-diabetic CKD.
Peter Ellis (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: